SPY305.15+0.83 0.27%
DIA254.93+0.64 0.25%
IXIC9,534.65+44.78 0.47%

JP Morgan Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $23

JP Morgan maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $22 to $23.

Benzinga · 05/12/2020 14:43

JP Morgan maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $22 to $23.